Financial Performance - The company's operating revenue for Q1 2022 was ¥206,049,845.51, representing an increase of 18.60% compared to ¥173,734,244.08 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2022 was ¥53,614,836.90, up 23.46% from ¥43,427,819.49 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥49,077,254.65, reflecting a 25.82% increase from ¥39,006,740.62 year-on-year[6]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.24, a 20.00% increase from ¥0.20 in the previous year[6]. - Total operating revenue for the first quarter reached ¥206,049,845.51, an increase of 18.5% compared to ¥173,734,244.08 in the previous year[34]. - Net profit for the period was ¥53,336,627.60, representing a 22.8% increase from ¥43,427,812.07 in the same quarter last year[36]. - Total comprehensive income for the period was CNY 53,336,627.60, compared to CNY 43,427,812.07 in the previous period, representing a growth of approximately 23.5%[40]. - Basic and diluted earnings per share increased to CNY 0.24 from CNY 0.20, reflecting a 20% increase[40]. Cash Flow - The net cash flow from operating activities decreased by 55.14% to ¥27,961,142.84, down from ¥62,324,682.53 in the same period last year[6]. - Cash inflow from operating activities was CNY 198,916,694.38, slightly down from CNY 200,900,983.53, indicating a decrease of about 1%[42]. - The company's total cash inflow from operating activities was CNY 198,916,694.38, while cash outflow was CNY 170,955,551.54, resulting in a net cash flow of CNY 27,961,142.84[42]. - Cash outflow for investing activities totaled CNY 107,925,200.78, down from CNY 341,804,650.87, a reduction of about 68%[47]. - Net cash flow from investing activities was negative at CNY -140,286.55, compared to CNY -45,331,843.78 in the previous period[47]. - Cash flow from financing activities resulted in a net outflow of CNY -17,034,520.27, compared to CNY -356,217.29 previously[47]. - The ending cash and cash equivalents balance was CNY 245,046,650.76, down from CNY 376,231,190.87, a decrease of approximately 34.8%[47]. - The company reported a decrease in cash received from investment recovery to CNY 105,000,000.00 from CNY 294,000,000.00, a decline of about 64.2%[46]. Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,535,133,046.49, a 1.00% increase from ¥1,519,881,333.25 at the end of the previous year[6]. - Total liabilities decreased to ¥124,170,461.08 from ¥150,250,223.95, a reduction of 17.4%[30]. - The company's equity attributable to shareholders rose to ¥1,406,060,373.19, up from ¥1,364,580,687.78, indicating a growth of 3.1%[33]. - The cash and cash equivalents increased to ¥1,212,452,945.83 from ¥1,196,020,727.99, reflecting a growth of 1.3%[33]. - The company reported a decrease in accounts payable from ¥24,021,136.22 to ¥16,276,754.19, a decline of 32.2%[30]. - The company’s deferred income tax assets increased to ¥21,056,557.57 from ¥20,457,300.33, showing a growth of 2.9%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,119[14]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[14]. - The total number of common shares held by the top ten shareholders accounts for a significant portion of the company's equity[14]. - The company has implemented a stock incentive plan, with a total of 2,123,700 restricted shares at the beginning of the period[21]. - The company has not identified any related party relationships among the top shareholders, except for a mother-daughter relationship between two of the shareholders[17]. Research and Development - Research and development expenses were ¥38,760,861.03, which is a 18.5% increase compared to ¥32,700,720.91 in the previous year[34]. - In January 2022, the PCR-11 gene product was included in Japan's medical insurance[22]. - In March 2022, the PD-L1 antibody reagent received approval from the National Medical Products Administration[22]. Expenses - Sales expenses for Q1 2022 were ¥61,722,822.00, an increase of 42.82% compared to ¥43,217,128.57 in the same period last year[10]. - Total operating costs amounted to ¥151,509,513.28, up from ¥125,941,512.78, reflecting a year-over-year increase of 20.4%[34]. - Investment income for Q1 2022 was ¥1,774,558.80, a significant increase of 210.40% from ¥571,701.45 in the previous year[13]. - The net cash flow from investing activities improved by 99.69%, with a net outflow of ¥140,286.55 compared to a much larger outflow of ¥45,331,843.78 in the same period last year[13].

Financial Performance - The company's operating revenue for 2021 was ¥917,033,391.28, representing a 25.90% increase compared to ¥728,390,555.97 in 2020[36]. - The net profit attributable to shareholders for 2021 was ¥239,573,622.91, a 32.86% increase from ¥180,326,353.21 in 2020[36]. - The net profit after deducting non-recurring gains and losses was ¥215,656,757.15, which is a 46.54% increase compared to ¥147,169,566.28 in 2020[36]. - The company's total assets at the end of 2021 were ¥1,519,881,333.25, up 17.56% from ¥1,292,897,713.11 at the end of 2020[36]. - The basic earnings per share for 2021 was ¥1.09, reflecting a 32.93% increase from ¥0.82 in 2020[36]. - The weighted average return on equity for 2021 was 19.19%, an increase from 17.84% in 2020[36]. - The net cash flow from operating activities for 2021 was ¥168,161,324.14, a decrease of 23.80% from ¥220,694,485.33 in 2020[36]. - The company reported a total of ¥173,734,244.08 in revenue for Q1 2021, with a net profit of ¥43,427,819.49[41]. - The company received government subsidies amounting to ¥19,459,460.20 in 2021, compared to ¥33,017,759.98 in 2020[44]. - The total net assets attributable to shareholders at the end of 2021 were ¥1,364,580,687.78, a 20.92% increase from ¥1,128,491,766.09 at the end of 2020[36]. Market Strategy and Expansion - The company aims to enhance its domestic market share and actively expand into international markets to ensure stable revenue growth[16]. - The company recognizes the increasing competition in the in vitro diagnostic market and is adapting its sales strategy to combine direct sales with distribution channels[17]. - The company intends to protect its intellectual property and core technologies while enhancing customer loyalty to maintain its competitive edge[17]. - The company is focused on improving operational management and utilizing information technology to optimize procurement, production, and sales processes[11]. - The company aims to expand its international strategy and strengthen overseas product registration and market access[79]. Research and Development - The company plans to strengthen its research and development capabilities to meet current and future market demands for in vitro diagnostic products[12]. - R&D investment for 2021 was 156 million yuan, representing a year-on-year growth of 35.63% and accounting for 17.02% of total revenue[87]. - The company has established a strong R&D team of 451 personnel, covering various fields such as molecular biology and clinical medicine[88]. - The company has developed and approved 24 single-gene and multi-gene diagnostic products, making it a leader in the industry with the most comprehensive product range[56]. - The company has received new medical device registrations for products including the SDC2 gene methylation testing kit, effective from January 5, 2021, to January 4, 2026[64]. Product and Service Offerings - The company operates in the rapidly growing molecular diagnostics sector, focusing on precision oncology, driven by increasing cancer incidence and aging population[51]. - The company's testing services business achieved revenue of 154.91 million yuan, representing a year-on-year growth of 33.43%[69]. - The company offers a wide range of cancer detection services, including lung cancer, colorectal cancer, and breast cancer, with service cycles typically ranging from 1 to 10 days[69]. - The company’s products have been approved in over 60 countries and regions, establishing partnerships with major pharmaceutical companies like AstraZeneca and Pfizer[56]. - The company’s testing reagent sales accounted for 76.23% of total revenue, amounting to approximately ¥699 million, with a year-on-year growth of 23.83%[114]. Risk Management - The company is aware of the risks associated with industry policy changes and is committed to monitoring market dynamics to mitigate potential impacts[9]. - The company has maintained a high gross margin but acknowledges potential risks from increased competition and rising costs, and plans to implement cost control measures[189]. - The company recognizes risks from industry policy changes and plans to enhance market analysis and management to mitigate these risks[185]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective oversight and operational coordination[196]. - The company has a board of directors consisting of 9 members, including 3 independent directors, complying with legal and regulatory requirements[199]. - The supervisory board consists of 3 members, including 1 employee representative, meeting legal and regulatory standards[200]. - The company maintains independence from its controlling shareholder in business, personnel, assets, institutions, and finance[198]. Investment and Financial Management - The total amount raised from the initial public offering (IPO) was RMB 277.2 million, with a net amount of RMB 247.23 million after deducting issuance costs of RMB 29.97 million[155]. - The company has committed to invest a total of RMB 83.89 million in the molecular diagnostic reagents and second-generation sequencer industrialization project, with 100% investment progress achieved by June 30, 2020[156]. - The company has achieved 100% investment progress for the project aimed at supplementing working capital and repaying bank loans, totaling RMB 5 million[159]. - The company has maintained strict control over expenditures, resulting in savings on project costs and ensuring the completion of investment projects[168]. - The company has generated investment income from cash management of idle funds, with a balance of RMB 11,697.64 in the special fund account after deducting fees[168].

Financial Performance - The company's revenue for Q3 2021 was ¥246,782,770.58, representing a 22.78% increase year-over-year, and total revenue for the year-to-date reached ¥645,735,626.15, up 33.41% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥65,233,520.52, a 43.92% increase year-over-year, while the year-to-date net profit reached ¥176,555,722.68, up 39.98%[6] - The basic earnings per share for Q3 2021 was ¥0.29, reflecting a 38.10% increase compared to the same period last year, with diluted earnings per share also at ¥0.29[6] - Total operating revenue for the third quarter reached ¥645,735,626.15, an increase of 33.4% compared to ¥484,020,471.55 in the same period last year[36] - Net profit for the period was ¥176,496,035.76, representing a 40% increase from ¥126,130,439.48 in the previous year[36] - Total comprehensive income attributable to the parent company was approximately CNY 176.07 million, an increase from CNY 125.94 million in the previous period, representing a growth of 40%[40] - Basic and diluted earnings per share increased to CNY 0.79 from CNY 0.57, reflecting a growth of 38.6%[40] Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥1,427,766,629.51, a 10.43% increase from the end of the previous year[6] - Total assets increased to ¥1,427,766,629.51, up from ¥1,292,897,713.11, marking a growth of 10.4%[34] - Total liabilities decreased to ¥123,931,289.91 from ¥164,405,947.02, a reduction of 24.5%[34] - The total liabilities amounted to ¥164,405,947.02, with current liabilities at ¥149,730,859.80[54] - The company reported a non-current liability of ¥14,675,087.22, which includes deferred income of ¥14,621,720.82[54] - The total equity attributable to shareholders of the parent company is ¥1,128,491,766.09[57] Cash Flow - The cash flow from operating activities for the year-to-date was ¥124,291,686.18, showing a decrease of 16.75% compared to the same period last year[6] - Cash inflow from operating activities totaled CNY 601.56 million, up from CNY 501.78 million, indicating a year-over-year increase of 19.9%[44] - Cash outflow from operating activities was CNY 477.27 million, compared to CNY 352.48 million in the previous period, resulting in a net cash flow from operating activities of CNY 124.29 million, down from CNY 149.30 million[44] - Investment activities generated a net cash outflow of CNY 75.96 million, an improvement from a net outflow of CNY 213.65 million in the previous period[44] - The company received CNY 5.25 million from financing activities, a decrease from CNY 72.80 million in the previous period[44] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,306, with the top 10 shareholders holding a combined 57.27%[16] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[16] - The number of shares held by the top 10 unrestricted shareholders includes Forward Investment (Hong Kong) Limited with 48,723,120 shares[16] - The company has a total of 2,123,700 restricted shares, all subject to unlocking according to the 2019 stock incentive plan[21] - The total number of restricted shares held by core management and technical personnel is 1,105,200, subject to unlocking regulations[21] - The company has not identified any related party relationships among the top shareholders, except for familial ties between certain partners[20] Operational Costs and Expenses - The company experienced a 70.09% increase in operating costs, totaling ¥103,791,219.27, mainly due to higher costs associated with multi-gene joint reagent products and increased testing service costs[12] - Total operating costs amounted to ¥457,191,133.58, up from ¥360,802,462.50, reflecting a year-over-year increase of 26.7%[36] - Research and development expenses were ¥109,167,134.77, which is a 26.2% increase compared to ¥86,512,568.40 from the same period last year[36] - The company's financial expenses increased by 112.83% to ¥2,284,183.71, primarily due to increased exchange losses[12] - The company reported a significant reduction in other payables, decreasing from ¥78,402,545.82 to ¥33,936,655.44, indicating improved financial management[31] Market Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[36] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[46] Other Financial Information - The company's cash and cash equivalents as of September 30, 2021, amount to ¥346,613,750.41, a decrease from ¥361,560,881.46 at the end of 2020[25] - Accounts receivable increased to ¥403,918,807.11 from ¥316,510,008.54 year-over-year[25] - Inventory has risen to ¥35,688,034.43, compared to ¥21,433,011.25 at the end of 2020[25] - The company reported a total asset value of CNY 1.29 billion, slightly down from CNY 1.29 billion in the previous period[51] - The total liabilities amounted to CNY 23.53 million, with accounts payable at CNY 14.04 million and contract liabilities at CNY 9.48 million[51] - The company has implemented new leasing standards starting from 2021, affecting prior comparative data[57] - The report indicates a capital reserve of ¥441,942,648.04 and a share capital of ¥221,808,000.00[54] - The company has a total of ¥78,402,545.82 in other payables, which includes employee compensation of ¥35,325,504.89[54] - The company reported a total of ¥2,050,135.96 in lease liabilities[54]

Business Performance - The company reported a stable and healthy development of its main business, focusing on international market expansion to mitigate operational risks from policy changes[8]. - The company achieved operating revenue of CNY 398,952,855.57, representing a year-on-year increase of 40.96%[28]. - The net profit attributable to shareholders was CNY 111,322,202.16, up 37.77% compared to the same period last year[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 100,787,048.75, reflecting a growth of 55.98% year-on-year[28]. - The basic earnings per share increased to CNY 0.50, a rise of 38.89% from CNY 0.36 in the previous year[28]. - The total assets at the end of the reporting period were CNY 1,358,178,931.59, marking a 5.05% increase from the end of the previous year[28]. - The net assets attributable to shareholders reached CNY 1,230,175,624.39, which is a 9.01% increase compared to the previous year[28]. Market Opportunities - The domestic in vitro diagnostic market is expected to grow rapidly due to economic development and healthcare reforms, presenting significant opportunities for the company[12]. - The molecular diagnostics market is expected to expand into broader applications, including genetic risk assessment and disease monitoring, driven by advancements in precision medicine technology[54]. - The demand for tumor precision medical diagnostic products is projected to increase annually due to the rising number of cancer patients and extended survival rates[58]. Product Development and Innovation - The company emphasizes the importance of continuous product innovation to maintain competitive advantages in the rapidly evolving in vitro diagnostic industry[9]. - The company's main business focuses on molecular diagnostics for cancer precision medicine, with a comprehensive product line and strong R&D capabilities[36]. - The company has obtained 45 patent authorizations and has developed 23 single-gene and multi-gene molecular diagnostic products approved by the NMPA[36]. - The company has developed proprietary technologies such as ADx-ARMS®, Super-ARMS®, and ddCapture®[75]. - The company has established independent third-party medical testing institutions, certified by the health authorities, to provide professional molecular testing services[47]. Financial Management - The company will not distribute cash dividends or issue bonus shares, focusing on reinvestment for growth[13]. - The company has received government subsidies contributing to 6.36% of total profit, amounting to ¥7,956,835.23[86]. - The total amount of raised funds is RMB 247.23 million after deducting issuance costs of RMB 29.97 million[98]. - The cumulative amount of raised funds invested is RMB 256.64 million, with no new investments during the reporting period[96]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[108]. Research and Development - The company reported a research and development investment of 68.16 million yuan, representing a year-on-year increase of 28.96% and accounting for 17.09% of total revenue[73]. - The company has established a strong R&D team of 338 personnel, including over 20 PhDs and nearly 200 master's degree holders[70]. - The company has been focusing on expanding its product offerings and enhancing its research and development capabilities[186]. Operational Efficiency - The company has implemented a strict management philosophy focused on cost control, quality assurance, and efficiency improvement, contributing to steady growth in its main business[60]. - The company employs a centralized procurement management system to ensure the quality and supply of raw materials for production[50]. - The production process for molecular diagnostic reagents includes automated steps, ensuring efficiency and compliance with regulatory standards[52]. International Expansion - The company has successfully entered markets in over 60 countries and regions, establishing partnerships with major pharmaceutical companies[36]. - The company has established an international business team covering over 60 countries and regions, actively seeking partnerships with local distributors and multinational pharmaceutical companies[53]. - The company is actively expanding its international market presence, with subsidiaries in Singapore, Hong Kong, and Canada[77]. Corporate Governance - The company has established a governance structure that ensures clear responsibilities and effective checks and balances, enhancing corporate governance levels[130]. - The company has not engaged in any major related party transactions during the reporting period, ensuring financial integrity[141]. - The company has maintained a commitment to improving information disclosure quality, ensuring equal access to information for all shareholders[130]. Shareholder Management - The company completed the first lock-up period release of the 2019 restricted stock incentive plan, with the listing date on May 12, 2021[160]. - A total of 85,500 restricted shares were repurchased and canceled during the reporting period[161]. - The total number of shares decreased from 221,808,000 to 221,722,500, reflecting a reduction of 85,500 shares[161]. - The company’s stock incentive plan includes provisions for unlocking shares based on performance and tenure[164]. Legal and Compliance - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[139]. - The company has not provided any guarantees that violate regulations during the reporting period, maintaining compliance[135]. - The half-year financial report has not been audited, which may affect the perception of financial transparency[136].

Financial Performance - The company's revenue for Q1 2021 was ¥173,734,244.08, representing a 91.65% increase compared to ¥90,653,754.15 in the same period last year[8] - Net profit attributable to shareholders was ¥43,427,819.49, up 67.59% from ¥25,912,928.63 year-on-year[8] - The net profit excluding non-recurring gains and losses reached ¥39,006,740.62, a significant increase of 183.25% from ¥13,771,012.38 in the previous year[8] - The net cash flow from operating activities was ¥62,324,682.53, reflecting a 30.25% increase compared to ¥47,850,460.42 in the same period last year[8] - Basic and diluted earnings per share were both ¥0.2, an increase of 11.11% from ¥0.18[8] - The company reported a significant increase in cash received from investment activities, totaling 296,472,807.09, compared to 30,293,194.52 in the previous period[105] - The total comprehensive income for the current period is 41,631,458.54, compared to 26,950,418.12 in the previous period, indicating a growth of about 54.4%[100] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,346,320,457.05, a 4.13% increase from ¥1,292,897,713.11 at the end of the previous year[8] - The company's total liabilities were CNY 166,291,899.72, slightly up from CNY 164,405,947.02, marking an increase of approximately 1.1%[72] - The equity attributable to shareholders of the parent company increased to CNY 1,180,028,564.75 from CNY 1,128,491,766.09, representing a growth of about 4.6%[75] - The company's total current assets reached CNY 1,029,349,983.25, up from CNY 1,008,764,262.12, indicating an increase of about 2.9%[66] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,695[12] - The largest shareholder is Forward Investment (Hong Kong) Limited, holding 21.97% with 48,723,120 shares[15] - The second largest shareholder is Hong Kong Central Clearing Limited, holding 6.88% with 15,260,868 shares[15] - The third largest shareholder is Xiamen Haicang Yixiang Investment Partnership (Limited Partnership), holding 6.69% with 14,834,700 shares[15] - The company has a total of 4,040,400 restricted shares, with 118,125 shares released during the reporting period[22] Research and Development - Research and development expenses increased by 54.36% to ¥32,700,720.91, up from ¥21,184,841.62, attributed to higher costs for R&D materials and personnel[26] - The company is committed to continuous product innovation and development to meet current and future market demands[38] - The company has a strong R&D capability and ongoing technical accumulation to support new product launches[38] Market Strategy - The company plans to continue expanding its market presence and product clinical applications, focusing on precision medicine and companion diagnostics[30] - The company aims to improve domestic market share and actively expand overseas markets to ensure stable revenue growth[39] - The company is focusing on enhancing product quality and customer loyalty to maintain competitive advantages amid increasing market competition[40] Investment and Financial Management - The total amount of raised funds is RMB 123.17 million, with 49.82% of the total raised funds having been redirected[46] - The company has invested RMB 534.44 million in the molecular diagnostic reagents and second-generation sequencing industrialization project, achieving 100% of the planned investment[46] - The company is closely monitoring market trends and industry changes to maximize the investment efficiency of raised funds[49] - The company has saved a portion of the raised funds by strictly controlling expenditures during the implementation of investment projects, leading to reduced actual spending[54] Operational Efficiency - The company emphasizes strict cost control and efficiency improvement to safeguard and enhance profitability[39] - The company experienced a 160.97% increase in operating costs, which reached ¥30,306,899.36, up from ¥11,613,132.86, in line with revenue growth[26] - The company is actively monitoring industry policy changes and enhancing its management practices to mitigate potential risks associated with regulatory adjustments[33] Miscellaneous - The company established a joint venture, Xiamen Xavi Health Technology Co., Ltd., with a registered capital of RMB 10 million, holding a 60% stake[41] - The company has not reported any violations regarding external guarantees during the reporting period[60] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[61] - The first quarter report was not audited, indicating that the financial results are preliminary[115]

Research and Development - The company reported a significant focus on research and development to meet market demands, ensuring a robust pipeline of in vitro diagnostic products[9] - The company is focused on attracting top talent through improved compensation and incentive mechanisms to support ongoing innovation[9] - R&D investment reached 115.11 million yuan, a year-on-year increase of 22.77%, accounting for 15.80% of operating revenue[79] - The company’s R&D team consists of 274 members, including over 20 PhDs and more than 100 master's degree holders[75] - The company plans to maintain its R&D investment levels in 2021, aiming to enhance its research capabilities and expedite key project advancements[191] - The company is committed to continuous innovation in technology and product development to provide comprehensive solutions for tumor precision medicine[191] Financial Performance - The company's operating revenue for 2020 was ¥728,390,555.97, representing a 25.94% increase compared to ¥578,355,544.11 in 2019[29] - The net profit attributable to shareholders for 2020 was ¥180,326,353.21, which is a 33.11% increase from ¥135,474,211.31 in 2019[29] - The basic earnings per share for 2020 was ¥0.82, down 12.77% from ¥0.94 in 2019[29] - The total assets at the end of 2020 were ¥1,292,897,713.11, a 23.51% increase from ¥1,046,774,057.97 at the end of 2019[29] - The net assets attributable to shareholders at the end of 2020 were ¥1,128,491,766.09, reflecting a 25.10% increase from ¥902,105,138.07 at the end of 2019[29] - The cash flow from operating activities for 2020 was ¥220,694,485.33, which is a 45.65% increase compared to ¥151,524,817.84 in 2019[29] - The company achieved a revenue of 728.39 million yuan in 2020, representing a year-on-year growth of 25.94%[92] - The net profit attributable to shareholders was 180.33 million yuan, an increase of 33.11% compared to the previous year[92] Market Expansion - The domestic market share is being actively increased while expanding into international markets to achieve stable revenue growth[12] - The company has established a strong presence in over 60 countries and regions, partnering with major pharmaceutical companies like AstraZeneca, Pfizer, and Merck for companion diagnostics[44] - The company aims to continue expanding its product offerings and market reach in the field of precision oncology diagnostics[44] - The company has expanded its international presence, with products now available in over 60 countries and regions[97] - The company will enhance its international market development efforts, including new product certifications and establishing deeper collaborations with tumor experts and pharmaceutical companies[196] Product Development and Innovation - The company has developed and launched innovative products such as ADx-ARMS®, Super-ARMS®, and ddCapture®, which cater to various tumor types and sample types for comprehensive management of cancer patients[45] - The Super-ARMS EGFR kit was the first product in China approved for marketing under the companion diagnostic reagent standard by the NMPA[44] - The company successfully developed and approved 23 molecular diagnostic products, including unique products in the domestic market[88] - The company launched several new products, including SDC2, PD-L1, and Classic panel, in response to clinical needs and market demands[92] - The company is advancing the development of PD-L1 (IHC platform) products, which are in the final stages of registration approval[109] Regulatory Environment - The company emphasizes the importance of monitoring policy changes in the healthcare sector, which could impact operations[7] - The regulatory environment is increasingly supportive of companion diagnostics, with multiple policies issued to promote and standardize the industry[65] Customer and Market Strategy - The company is actively exploring a combination of direct sales and distribution channels to enhance market penetration and product recognition[13] - The sales strategy combines direct sales and distribution, with a domestic sales team of over 300 people and an international business team covering over 60 countries[61] - The company aims to strengthen its domestic marketing network, focusing on direct sales while expanding its coverage and penetration in key cancer areas[195] Cost Management - The company has implemented strict cost control measures to safeguard and improve profitability amidst rising operational costs[9] - The main business costs for testing reagents amounted to ¥32,094,739.46, accounting for 33.80% of total operating costs, a decrease from 42.91% in 2019[133] - The main business costs for testing services reached ¥35,251,647.58, representing 37.13% of total operating costs, an increase of 81.94% compared to ¥19,375,777.47 in 2019[133] Talent and Human Resources - The company has established a talent strategy focusing on attracting and nurturing high-quality professionals, granting 790,500 restricted stock units to 102 core management and technical personnel[113] - The company will prioritize human resource development, particularly in R&D and sales positions, to strengthen its competitive advantage[199] Investment and Financial Management - The total amount of raised funds was ¥247,230,000.00, with ¥10,947.19 million utilized during the reporting period, representing 49.82% of the total raised[160] - The company generated interest income from idle funds, contributing to the surplus of raised funds[175] - The company has decided to terminate the molecular diagnostic reagents and second-generation sequencing instrument industrialization project to maximize investment efficiency and reduce risks, reallocating the remaining funds for working capital[168]

厦门艾德生物医药科技股份有限公司 2020 年第三季度报告全文 厦门艾德生物医药科技股份有限公司 2020 年第三季度报告 2020-077 2020 年 10 月 1 厦门艾德生物医药科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人 LI-MOU ZHENG、主管会计工作负责人陈英及会计机构负责 人（会计主管人员）陈英声明：保证季度报告中财务报表的真实、准确、完整。 2 厦门艾德生物医药科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------------------------------|------------- ...

Financial Performance - The company reported a strong performance in the first half of 2020, with a revenue increase of 20% compared to the same period last year[26]. - The company's operating revenue for the reporting period was ¥283,028,216.16, representing a 6.44% increase compared to ¥265,910,192.32 in the same period last year[33]. - The net profit attributable to shareholders was ¥80,804,558.07, a 3.38% increase from ¥78,162,636.38 year-on-year[33]. - The net cash flow from operating activities was ¥89,311,262.07, reflecting a 9.41% increase compared to ¥81,633,165.04 in the previous year[33]. - The company achieved a revenue of 282.83 million CNY, representing a year-on-year growth of 6.44%[93]. - The net profit attributable to shareholders was 80.80 million CNY, an increase of 3.38% year-on-year; excluding stock incentive costs, the adjusted net profit was 109.03 million CNY, up 24.56% from the previous year[93]. Market Strategy and Expansion - The company is focused on expanding its market share, particularly in the domestic market, while also actively exploring opportunities in overseas markets[12]. - The company aims to achieve stable revenue growth by expanding both domestic and international markets[172]. - The company has established a strong market presence, with products sold in over 50 countries and regions, gaining recognition from major pharmaceutical companies[43]. - The company is actively seeking partnerships with local distributors and multinational pharmaceutical companies in over 50 countries and regions globally[71]. - The company has established a new subsidiary, AMOYDX (SINGAPORE) PTE.LTD., which is currently in the investment phase and does not significantly impact overall performance[166]. Research and Development - The company has a robust R&D pipeline that aligns with current and future market demands for in vitro diagnostic products, ensuring a steady flow of new product launches[11]. - The company invested 52.86 million yuan in R&D, a 30.38% increase year-on-year, representing 18.68% of its operating revenue[84]. - The company has developed 22 types of single-gene and multi-gene detection reagents, many of which are the first in China to obtain NMPA medical device registration and CE certification[43]. - The company has launched online academic promotion initiatives to enhance awareness of its innovative products among healthcare professionals and patients[98]. - The company is advancing the development of tumor immune therapy detection products, with high sensitivity and specificity, currently in the technical review stage for registration[95]. Product and Service Offerings - The company's testing reagent business achieved operating revenue of ¥225,648,200, which is a significant contribution to overall revenue[47]. - The company’s products include various gene mutation detection kits related to targeted therapies for multiple cancers, such as lung cancer and colorectal cancer[48]. - The company’s detection services cover a range of cancers, including lung, colorectal, breast, ovarian, and thyroid cancers[64]. - The company has established 7 major testing technology platforms, including ADx-ARMS, Super-ARMS, NGS, ddPCR, FISH, and IHC, adhering to CAP and CLIA standards for management and quality control[63]. Financial Management and Investments - The company reported a significant increase in trading financial assets by 802.23% compared to the beginning of the period, primarily due to the purchase of principal-protected floating income structured financial products[79]. - The company has permanently supplemented working capital with CNY 8,717.24 million, achieving 100% of the investment progress[136]. - The total committed investment for all projects is CNY 24,723 million, with a cumulative investment of CNY 24,932.9 million[136]. - The company has utilized part of the idle raised funds for cash management, generating certain investment income during the reporting period[141]. Risk Management - The company acknowledges the risks associated with regulatory changes in the healthcare sector, which could impact its operations and market environment[7]. - The company is actively monitoring policy changes in the healthcare sector to mitigate risks associated with regulatory adjustments[167]. - The company is facing risks related to potential declines in gross margin due to increased market competition and rising costs[172]. Corporate Governance - The company is committed to not distributing cash dividends or issuing bonus shares, focusing instead on reinvesting profits for growth[17]. - The company held its first extraordinary general meeting of 2020 on March 3, with an investor participation rate of 54.24%[177]. - The half-year financial report has not been audited[182]. - The company has no overdue commitments from its actual controllers, shareholders, or related parties[188]. Compliance and Legal Matters - The company reported no major litigation or arbitration matters during the reporting period[184]. - The company has not experienced any penalties or rectification issues during the reporting period[185]. - The company did not engage in any research, communication, or interview activities during the reporting period[175].

Financial Performance - Total revenue for Q1 2020 was ¥90,653,754.15, a decrease of 23.96% compared to ¥119,225,588.02 in the same period last year[8] - Net profit attributable to shareholders was ¥25,912,928.63, down 20.48% from ¥32,586,272.94 year-on-year[8] - Net profit excluding non-recurring gains and losses was ¥13,771,012.38, a significant decline of 47.56% from ¥26,258,255.13 in the previous year[8] - Basic earnings per share decreased by 21.74% to ¥0.18 from ¥0.23 year-on-year[8] - The total profit for the current period is ¥29,407,499.50, down from ¥37,774,707.38, reflecting a decrease of 22.5%[79] - The net profit for the current period is 26,950,418.12, a decrease of 10.5% compared to 30,112,380.97 from the previous period[87] - Operating profit decreased to 30,954,076.20, down from 34,582,729.47, reflecting a decline of approximately 7.5%[87] - The total comprehensive income for the current period is 26,950,418.12, compared to 30,112,380.97 in the previous period, showing a decline of approximately 10.5%[90] Cash Flow - Operating cash flow for the period increased by 61.18% to ¥47,850,460.42, compared to ¥29,687,418.31 in the same period last year[8] - The net cash flow from operating activities increased by 61.18% to ¥47,850,460.42, driven by improved collection of accounts receivable and government subsidies[27] - Cash flow from operating activities increased to 142,133,391.30, compared to 119,670,257.73 in the previous period, representing a growth of about 18.7%[91] - The net cash flow from financing activities increased by 479.52% to ¥44,415,500.89, primarily due to increased bank loans[27] - The cash inflow from financing activities was 44,800,000.00, compared to a cash outflow of 11,702,940.60 in the previous period, indicating a positive shift in financing[97] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,116,983,104.07, reflecting a growth of 6.71% from ¥1,046,774,057.97 at the end of the previous year[8] - Total current assets increased to CNY 866,881,818.61 as of March 31, 2020, up from CNY 797,408,985.41 at the end of 2019, representing an increase of approximately 8.5%[57] - Total liabilities increased to CNY 174,311,147.78 from CNY 144,668,919.90, reflecting an increase of approximately 20.5%[66] - Total liabilities amount to ¥170,604,867.73, an increase of 24.7% from ¥136,751,370.44 in the previous period[73] - The company's equity attributable to shareholders rose to CNY 942,671,956.29 from CNY 902,105,138.07, an increase of about 4.5%[66] Inventory and Expenses - Inventory rose by 58.13% to ¥27,138,184.89, mainly due to increased material stocking[24] - Operating expenses decreased by 55.31% to ¥21,665,214.65, largely due to reduced marketing activities amid the COVID-19 pandemic[24] - Research and development expenses for the current period are ¥21,184,841.62, an increase of 9.6% from ¥19,334,079.42 in the previous period[76] Shareholder Information - The company reported a total of 11,996 shareholders at the end of the reporting period[13] - The largest shareholder, Foresee Investment (Hong Kong) Co., Ltd., held 23.07% of the shares, totaling 33,961,680 shares[13] Government and Subsidies - Government subsidies recognized in the current period amounted to ¥13,938,661.15[9] - The company experienced a 134.87% rise in other income to ¥13,938,661.15, mainly from increased government subsidies[24] Research and Development - The company has a strong R&D pipeline that meets current and future market demands for in vitro diagnostic products[32] - The company is committed to attracting top talent through improved compensation and incentive mechanisms to support its R&D efforts[32] - The company has completed 97.04% of the investment in the R&D center expansion project as of the reporting period[43] - The company has decided to terminate the "Molecular Diagnostic Reagents and Second-Generation Sequencer Industrialization Project" due to changes in market conditions and technology trends, reallocating the remaining funds to permanently supplement working capital[46] Market Strategy - The company is actively expanding its overseas market to achieve stable revenue growth[36] - The company emphasizes the importance of continuous product innovation to maintain its competitive edge in the rapidly evolving in vitro diagnostics industry[32] - The company plans to enhance customer loyalty and product quality to navigate the intensifying competition in the in vitro diagnostics market[37] Compliance and Management - The company has adhered to regulations regarding the use of fundraising funds, ensuring project quality and controlling implementation risks[49] - There are no violations regarding the use of fundraising funds or non-operating occupation of funds by controlling shareholders during the reporting period[52][53] - The company has implemented a management philosophy focused on cost control, quality improvement, and efficiency enhancement to safeguard its profitability[33]

Financial Performance - The company reported a strong performance in 2019, with a revenue increase of 20% compared to the previous year, reaching RMB 500 million[24]. - The company's operating revenue for 2019 was ¥578,355,544.11, representing a 31.73% increase compared to ¥439,031,481.74 in 2018[31]. - The net profit attributable to shareholders for 2019 was ¥135,474,211.31, a 6.89% increase from ¥126,737,914.51 in 2018[31]. - The net profit after deducting non-recurring gains and losses was ¥117,091,439.11, up 8.30% from ¥108,113,554.39 in 2018[31]. - The net cash flow from operating activities increased by 62.15% to ¥151,524,817.84 from ¥93,448,159.37 in 2018[31]. - The total assets at the end of 2019 were ¥1,046,774,057.97, a 27.85% increase from ¥818,746,842.78 at the end of 2018[31]. - The basic earnings per share for 2019 was ¥0.94, up 6.82% from ¥0.88 in 2018[31]. - The company achieved a revenue of 578.36 million yuan, representing a year-on-year growth of 31.73%[86]. - The net profit attributable to shareholders was 135.47 million yuan, an increase of 6.89% compared to the previous year[86]. Market Strategy and Expansion - The company plans to distribute a cash dividend of RMB 2.5 per 10 shares to all shareholders, based on the total share capital as of the dividend distribution date[15]. - The company is focusing on expanding its market share domestically and internationally, aiming for a 15% increase in market penetration in the next fiscal year[10]. - The company is committed to enhancing its sales model by combining direct sales with distribution channels to increase customer engagement and product recognition[15]. - The company has established an international business team covering over 50 countries and regions, actively seeking cooperation with local distributors and multinational pharmaceutical companies[61]. - The company aims to increase international market development efforts, including new product certifications and market access, while strengthening collaboration with oncology experts and pharmaceutical companies[181]. Research and Development - The R&D pipeline is robust, with ongoing projects aimed at developing new diagnostic products to meet market demands, ensuring timely registration and approval[9]. - R&D investment reached 93.75 million yuan, up 19.68% year-on-year, accounting for 16.21% of total revenue[88]. - The company has a strong focus on R&D and has developed proprietary technologies such as ADx-ARMS®, Super-ARMS®, and ddCapture®[69]. - The company is committed to providing comprehensive solutions for tumor precision medicine and aims to become a leading international enterprise in this field[177]. - The company plans to continue its research and development efforts in tumor immunotherapy detection products and strengthen strategic cooperation with multinational pharmaceutical companies[180]. Product Development and Compliance - The company’s main business is focused on the research, production, and sales of molecular diagnostic products for precision oncology, with a product line that includes 22 single-gene and multi-gene testing reagents[44]. - The company has obtained 22 Class III medical device registration certificates and 1 Class II medical device registration certificate, ensuring compliance with regulatory standards[50]. - The company has developed 22 tumor precision medical molecular diagnostic reagents, making it one of the most comprehensive product lines in the industry[82]. - The ROS1 testing kit has been approved for sale in Japan and South Korea, marking it as the first tumor companion diagnostic reagent from a Chinese company to gain overseas approval[44]. - The EGFR testing kit is the first product in China to be approved under the companion diagnostic reagent standard by the NMPA[44]. Financial Management and Investments - The company received government subsidies amounting to ¥22,365,505.55 in 2019, an increase from ¥15,517,970.41 in 2018[38]. - The company has fully utilized the RMB 50 million allocated for supplementary working capital and bank loan repayment[156]. - The total amount of committed investment projects is RMB 247.23 million, with RMB 55.02 million used in the current reporting period[156]. - The company has not changed the purpose of the raised funds, with RMB 36 million (14.56%) remaining unused[152]. - The company has not violated any regulations regarding the use of raised funds and has received approval for cash management of temporarily idle funds up to RMB 160 million[162]. Risk Management - The company is actively monitoring policy changes in the healthcare sector to mitigate potential risks associated with regulatory adjustments[6]. - The company faces risks from potential changes in industry policies, which could adversely affect its operations, and it actively monitors policy dynamics to mitigate these risks[186]. - The company recognizes the risk of declining gross margins due to increased market competition and rising labor costs, and it aims to enhance profitability through cost control and market expansion[188]. Talent Management - The company has implemented a talent retention strategy, focusing on competitive compensation and incentive mechanisms to attract skilled professionals[9]. - The company emphasizes talent acquisition and retention, implementing competitive incentive mechanisms and stock option plans for core employees[183]. Dividend Policy - The company reported a cash dividend of 2.5 yuan per 10 shares and a total cash dividend amount of 36,795,250 yuan, representing 100% of the distributable profit[197]. - The proposed profit distribution plan for 2019 includes a cash dividend of 2.5 yuan (after tax) for every 10 shares held[200]. - The remaining undistributed profits will be carried forward to the next fiscal year[200].